Salvage therapy in patients with advanced non-small cell lung cancer

Pablo M. Bedano, Nasser Hanna

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Patients with advanced non-small cell lung cancer continue to have a poor prognosis; most die from the disease within 1 year. Chemotherapy is beneficial for some patients in the first-line metastatic setting. Three agents, namely docetaxel, pemetrexed, and erlotinib, are approved by the United States Food and Drug Administration as treatment in the second-line setting. In this article, we examine the data supporting the use of these agents in the second-line setting and review data from other completed trials. Lastly, we propose strategies to advance the treatment of patients with non-small cell lung cancer.

Original languageEnglish
Pages (from-to)582-587
Number of pages6
JournalJournal of Thoracic Oncology
Volume1
Issue number6
DOIs
StatePublished - Jul 2006

Fingerprint

Salvage Therapy
Non-Small Cell Lung Carcinoma
docetaxel
Pemetrexed
United States Food and Drug Administration
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Salvage therapy in patients with advanced non-small cell lung cancer. / Bedano, Pablo M.; Hanna, Nasser.

In: Journal of Thoracic Oncology, Vol. 1, No. 6, 07.2006, p. 582-587.

Research output: Contribution to journalArticle

@article{bd4dfe1da4f748b2bdd0ba37be5ef60f,
title = "Salvage therapy in patients with advanced non-small cell lung cancer",
abstract = "Patients with advanced non-small cell lung cancer continue to have a poor prognosis; most die from the disease within 1 year. Chemotherapy is beneficial for some patients in the first-line metastatic setting. Three agents, namely docetaxel, pemetrexed, and erlotinib, are approved by the United States Food and Drug Administration as treatment in the second-line setting. In this article, we examine the data supporting the use of these agents in the second-line setting and review data from other completed trials. Lastly, we propose strategies to advance the treatment of patients with non-small cell lung cancer.",
author = "Bedano, {Pablo M.} and Nasser Hanna",
year = "2006",
month = "7",
doi = "10.1097/01243894-200607000-00015",
language = "English",
volume = "1",
pages = "582--587",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "6",

}

TY - JOUR

T1 - Salvage therapy in patients with advanced non-small cell lung cancer

AU - Bedano, Pablo M.

AU - Hanna, Nasser

PY - 2006/7

Y1 - 2006/7

N2 - Patients with advanced non-small cell lung cancer continue to have a poor prognosis; most die from the disease within 1 year. Chemotherapy is beneficial for some patients in the first-line metastatic setting. Three agents, namely docetaxel, pemetrexed, and erlotinib, are approved by the United States Food and Drug Administration as treatment in the second-line setting. In this article, we examine the data supporting the use of these agents in the second-line setting and review data from other completed trials. Lastly, we propose strategies to advance the treatment of patients with non-small cell lung cancer.

AB - Patients with advanced non-small cell lung cancer continue to have a poor prognosis; most die from the disease within 1 year. Chemotherapy is beneficial for some patients in the first-line metastatic setting. Three agents, namely docetaxel, pemetrexed, and erlotinib, are approved by the United States Food and Drug Administration as treatment in the second-line setting. In this article, we examine the data supporting the use of these agents in the second-line setting and review data from other completed trials. Lastly, we propose strategies to advance the treatment of patients with non-small cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=34247893976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247893976&partnerID=8YFLogxK

U2 - 10.1097/01243894-200607000-00015

DO - 10.1097/01243894-200607000-00015

M3 - Article

C2 - 17409922

AN - SCOPUS:34247893976

VL - 1

SP - 582

EP - 587

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 6

ER -